Ranbaxy Disappointed By U.S. FDA’s Warning Letters And “Import Alert”
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - India's largest drug maker Ranbaxy expressed its disappointment over U.S. FDA's move to issue warning letters and import alerts against drug products manufactured at its sites in Dewas in Madhya Pradesh and Paonta Sahib in Himachal Pradesh